CRDL.TO
Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 78,760 | 0 | 0 | 0 | 0 |
| Net Income | (33.82M) | (36.68M) | (28.13M) | (11.52M) | (24.72M) | (20.65M) | (13.98M) | (15.89M) | (1.66M) |
| EPS | -0.39 | -0.51 | -0.44 | -0.18 | -0.57 | -0.69 | -0.54 | -1.03 | -0.07 |
| Free Cash Flow | (23.88M) | (25.08M) | (25,244) | (27.30M) | (23.56M) | (9.23M) | (11.80M) | (10.91M) | (1.32M) |
| FCF / Share | -0.27 | -0.35 | -0.00 | -0.44 | -0.55 | -0.31 | -0.46 | -0.71 | -0.06 |
| Operating CF | (23.85M) | (25.06M) | (25,180) | (27.22M) | (23.55M) | (9.19M) | (11.38M) | (10.89M) | (1.29M) |
| Total Assets | 23.62M | 31.86M | 36.70M | 62.03M | 87.88M | 15.89M | 15.50M | 24.68M | 3.22M |
| Total Debt | 125,523 | 158,532 | 158,532 | 72,871 | 117,579 | 156,566 | 190,752 | 269,216 | 190,043 |
| Cash & Equiv | 21.42M | 30.58M | 34.93M | 59.47M | 83.90M | 14.03M | 6.96M | 16.73M | 2.36M |
| Book Value | 17.88M | 24.73M | 28.25M | 52.20M | 76.24M | 13.27M | 14.67M | 22.27M | 2.85M |
| Return on Equity | -1.89 | -1.48 | -1.00 | -0.22 | -0.32 | -1.56 | -0.95 | -0.71 | -0.58 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.82M) | (7.21M) | (9.96M) | (8.35M) | (8.29M) | (8.18M) | (12.73M) | (6.59M) | (9.18M) | (7.64M) | (5.93M) | (7.47M) |
| EPS | -0.10 | -0.07 | -0.12 | -0.10 | -0.10 | -0.10 | -0.18 | -0.10 | -0.14 | -0.12 | -0.09 | -0.12 |
| Free Cash Flow | (7.57M) | (5.23M) | (6.93M) | (4.56M) | (7.17M) | (5.60M) | (7.78M) | (4.78M) | (6.93M) | (6.48M) | (3.42M) | (5.36M) |
| FCF / Share | -0.07 | -0.05 | -0.08 | -0.06 | -0.09 | -0.07 | -0.11 | -0.07 | -0.10 | -0.10 | -0.05 | -0.08 |
| Operating CF | (7.52M) | (5.23M) | (6.93M) | (4.55M) | (7.15M) | (5.59M) | (7.77M) | (4.78M) | (6.92M) | (6.46M) | (3.41M) | (5.35M) |
| Total Assets | 31.41M | 23.62M | 12.95M | 19.94M | 25.45M | 31.86M | 17.52M | 26.31M | 31.13M | 36.70M | 43.05M | 47.17M |
| Total Debt | 116,408 | 125,523 | 134,199 | 142,554 | 150,660 | 158,532 | 165,984 | 164,273 | 167,136 | 174,340 | 181,206 | 48,194 |
| Cash & Equiv | 27.67M | 21.42M | 11.62M | 18.20M | 23.29M | 30.58M | 15.89M | 24.02M | 28.57M | 34.87M | 40.54M | 44.94M |
| Book Value | 24.20M | 17.88M | 9.56M | 11.81M | 17.59M | 24.73M | 10.43M | 15.36M | 20.06M | 28.25M | 34.87M | 38.75M |
| Return on Equity | -0.45 | -0.40 | -1.04 | -0.71 | -0.47 | -0.33 | -1.22 | -0.43 | -0.46 | -0.27 | -0.17 | -0.19 |
